Clinical trial
Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically…
NCT00047333 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00047333 |
|---|---|
| Title | Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed |
| Official title | A Phase 2 Open-Label Study Of OSI-774 (NSC 718781) In Unresectable Hepatocellular Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer |
| Intervention type | Drug, Other |
| Interventions | erlotinib hydrochloride, laboratory biomarker analysis, pharmacological study |
| Enrollment | 80 |
| Start date | Aug 1, 2002 |
| Primary completion | Jan 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 23, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: